Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Translational & Genomics Biology

Translational & Genomics Biology

The translational and genomics biology group provides services that cater to the continuum of drug discovery programs in Immuno-oncology pertaining to translational and genomics aspects. We bring to the table experience across both small molecules and biologics, antibody discovery and Integrated research, development of new assays, developing translational models using human immune cells, phenotyping, and characterization. We have availability of human samples from healthy and diseased populations and a wide range of assays including target cell killing assays, immune cell activation, MLR, mast cell degranulation, neutrophil activation, and cytokine release assays. We also offer flow cytometry, live cell imaging, and multiplex platforms for biomarker studies. We are equipped with a 96 capillary DNA analyzer (ABI) for Sanger sequencing and two platforms (Illuminaâ„¢ MiSeq and Illuminaâ„¢ NextSeq) for next-generation sequencing (NGS).

Our NGS technology enables profiling of DNA and RNA at very high throughputs and high resolution to address a variety of biological questions. The technology can be exploited at early discovery stages (lead identification, target-discovery, validation, mechanism of action), as well as during later stages (in vitro/in vivo studies, tumor biology, PDx models, biomarker discovery, genome editing, CDx development, patient stratification for trial design, drug repurposing).

The Syngene NGS facility offers a range of sequencing services that include the following:

  • Whole genome sequencing (de novo and resequencing)
  • Targeted resequencing (custom amplicon panels)
  • Exome sequencing
  • Transcriptome sequencing
  • ChIP-sequencing
  • Microbiome sampling by 16s rDNA sequencing
  • Whole genome shotgun metagenomics

Our services include initial experimental design, sample processing (library preparation), sequencing, and tiered analysis based on requirements of the client.

Team Title

Designation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details